Trials / Completed
CompletedNCT01028950
YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness
A Multi-center, Open Label Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients with acute medical illness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM150 | oral |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2009-12-09
- Last updated
- 2010-06-16
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01028950. Inclusion in this directory is not an endorsement.